Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Revised Strategic Plan Emphasizes Countermeasures, Biosimilars

This article was originally published in The Pink Sheet Daily

Executive Summary

Other aspects of FDA's approach to drugs and biologics remain the same as they were in last September's draft version of the agency's five-year plan.

You may also be interested in...



"Virtual Patients," Medical Countermeasures On FDA Regulatory Science Horizon

The agency is planning a library of validated computer models of how patients respond to medical treatments.

"Virtual Patients," Medical Countermeasures On FDA Regulatory Science Horizon

The agency is planning a library of validated computer models of how patients respond to medical treatments.

Regulatory Science Next To Be Outsourced?

CDER report calls for broader partnerships with outside bodies in regulatory science.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS072137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel